Dr. Kristina Hazard is a pharmacist who is specialized in Oncology in Kennesaw, Georgia. Patients can reach her at 750 Townpark Ln Nw, Kennesaw or contact her on 770-514-5483. Active license number of Dr. Kristina Hazard is RPH025940 for Oncology in Georgia. Dr. Kristina Hazard is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Dr. Kristina Hazard speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Kristina Hazard
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
750 Townpark Ln Nw, Kennesaw, Georgia, 30144-5579
Phone:
770-514-5483
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Kristina Hazard are as mentioned below.
NPI Number:
1457859365
NPI Enumeration Date:
25 Jan, 2018
NPI Last Update On:
25 Jan, 2018
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Kristina Hazard are as mentioned below.
Specialization
License Number
State
Status
Oncology
RPH025940
Georgia
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1922 Enchanted Woods Trl, Marietta, Georgia
Zip:
30066-1979
Phone Number:
--
Fax Number:
--
Patients can reach Dr. Kristina Hazard at 750 Townpark Ln Nw, Kennesaw, Georgia or can call on phone at 770-514-5483.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.